Compute Beyond Nature
Vilya pioneers computational drug design to create de novo macrocycles — entirely new molecules inspired by biology but designed from first principles through AI-driven methods.
Inspired by nature. Designed by Vilya.
Born from Nobel Prize-winning research at the Institute for Protein Design, we're creating medicines evolution never imagined. Our computational platform doesn't mimic biology — it extends beyond it, designing therapeutic molecules with atomic precision.
AI-Driven macrocycle design
Our platform generates, predicts and validates entirely new macrocycles in silico. These macrocycles combine the selectivity of biologics with the convenience of pills — opening doors to previously untreatable diseases.
Our pipeline
We are advancing orally bioavailable macrocycles that could replace today's injectable biologics. Each molecule is computationally designed to hit its target with precision while crossing biological barriers that stop traditional drugs.
Internal: Oral / Permeable Drugs
Oncology Target A
Oncology Target B
integrin α4β7 for IBD
Immunology Target C
Immunology Target D
Vilya in the news
From our founder's Nobel Prize to breakthrough publications in science, we're pushing the boundaries of what's possible in drug design.
Our scientific founder, Dr. David Baker, has been awarded the 2024 Nobel Prize in Chemistry for his pioneering work in computational protein design. The science behind Vilya’s mission builds directly upon Dr. Baker’s original discovery by applying advanced computational approaches to design novel, chemically diverse macrocycles to target disease biology with unprecedented precision.
Join our mission
We're assembling a team of computational biologists, chemists, and builders who believe the best medicines haven't been discovered — they need to be designed.
Let’s build the future of therapeutics
Whether you're exploring partnership, investment, or collaboration — we'd love to hear from you.
Next